[Cyproterone acetate in benign prostatic hypertrophy].
The literature reports that the use of an anti-androgen receptor like CPA is capable of reducing the epithelial component of BPH. The clinical results of the treatment carried out in 20 patients suffering from BPH with a prevalent epithelial component are presented.
Cocimano
V
V
Marino
G
G
Surleti
D
D
Brigato
R
R
Griffa
D
D
D000368:Aged; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology
D017373:Cyproterone Acetate; D003534:Cyproterone
Il ciproterone acetato nella iperperplasia prostatica benigna.